Citi raised the firm’s price target on Ardelyx to $12 from $10 and keeps a Buy rating on the shares. The firm says Xphozah delivered an “exceptional” Q2 with $37.1M in sales, handily beating consensus of $20.2M.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDX:
- Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
- Ardelyx announces publication of two plain language summaries from XPHOZAH
- Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion
- ARDX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Ardelyx lawsuit unlikely to succeed, says H.C. Wainwright
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue